Advances in the treatment of relapsing-remitting multiple sclerosis.

@article{Tanasescu2014AdvancesIT,
  title={Advances in the treatment of relapsing-remitting multiple sclerosis.},
  author={Radu Tanasescu and Carolina Ionete and I J Chou and Cris S. Constantinescu},
  journal={Biomedical journal},
  year={2014},
  volume={37 2},
  pages={41-9}
}
This article reviews and discusses the approved and emerging therapies for multiple sclerosis (MS). MS is a chronic and disabling immune-mediated disease of the central nervous system (CNS) that affects mainly young adults. MS imposes a huge economic burden on healthcare systems and the society. Although the last 20 years have brought a continuous expansion in therapeutic options, there are still unmet needs in MS management. Available MS drugs have varying degrees of efficacy in reducing… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 86 references

Emerging injectable therapies for multiple sclerosis.

The Lancet. Neurology • 2013
View 7 Excerpts
Highly Influenced

Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy.

Therapeutic advances in chronic disease • 2013
View 8 Excerpts
Highly Influenced

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

The New England journal of medicine • 2012
View 5 Excerpts
Highly Influenced

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

The New England journal of medicine • 2011
View 2 Excerpts
Highly Influenced

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

The New England journal of medicine • 2010
View 6 Excerpts
Highly Influenced

Oral fingolimod (FTY720) treatment reduces peripheral IL‐17‐producing TH17 cells in patients with multiple sclerosis

M Mehling, RL Lindberg, +3 authors V. Brinkmann
Mult Scler 2008;14:S234‐S • 2014
View 1 Excerpt

Similar Papers

Loading similar papers…